As per the contract it is a special pact that will render rights to their XMetA program of allosteric
monoclonal antibodies that upu-regulate the insulin receptor to Novo Nordisk A/S.
Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder, is a novel, proprietary negative allosteric
modulator of the alpha-7 ([eth]7) nicotinic acetylcholine receptor.
Specifically, the Beactica scientists applied an efficient and innovative SPR biosensor-based screening approach to identify novel allosteric
modulators to this challenging drug target.
Research Reported in PNAS Demonstrates Allosteric
Activation of CXCR4 Receptor to Mobilize Bone Marrow Hematopoietic Stem Cells -
CompleGen's XenoGene[TM] technology uses the power of genetics to identify allosteric
inhibitors that are selective for specific protein targets.
OXY111A, a novel allosteric
modulator of affinity of oxygen to hemoglobin, was selected for inclusion in this prestigious list by a committee that included independent experts in cardiovascular and metabolic diseases as well as representatives from Windhover Information, the publishers of IN VIVO and Start-Up.
This is followed by discussion of the scientific developments enabling the pursuit of new approaches such as allosteric
modulation, bifunctional ligand design, and the targeting of dimeric receptors.
Riedel will work closely with the NormOxys management team to support the advancement of its lead drug candidate, OXY111A, a novel allosteric
modulator of affinity of oxygen to hemoglobin which is currently being evaluated in clinical studies as a treatment for cardiovascular diseases and cancers.
Enzyme Inhibitors Drug-Design: Highly Specific, Potent and Drug-able Enzyme Inhibitors
is a highly selective non-ATP competitive allosteric
inhibitor of AKT currently being evaluated in early-phase clinical trials for treatment of cancer patients with solid tumors.
Identification and Classification of Allosteric
This combination of tools applied to crystallographically well-defined drug binding pockets yield higher quality GPCR clinical candidates, including allosteric
and bitopic small molecules, before the expensive commitment of clinical trials.